EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Martijn van den Bosch

Work experience

2024 – present Assistant Professor at Department of Rheumatology, Radboud Universitair Medisch Centrum, the Netherlands
2021 – present Tenure track researcher at Experimental Rheumatology studying the involvement of synovial inflammation in osteoarthritis
2017 – 2020 Postdoctoral research fellow at Experimental Rheumatology, studying the involvement of synovial inflammation in osteoarthritis
2010 – 2017 PhD student at Experimental Rheumatology, studying the role of Wnt signaling in osteoarthritis
2008 – 2008 Short introduction into animal testing, basic animal handling and in vivo experimentation at Department of Autoimmunity, Schering-Plough, Oss, the Netherlands

2008 – 2008 Master internship at Department of Autoimmunity, Schering-Plough, Oss, the Netherlands under the supervision of Dr. R. Smeets. The effects of inhibition of tyrosine kinase on T cell apoptosis were studied
2007 – 2007 Master internship at Department of Blood Transfusion and Transplantation Immunology, University Medical Center, Nijmegen, the Netherlands under the supervision of Dr. H. Koenen. Binding of nuclear proteins from regulatory T cell populations to the Foxp3 promoter region was studied
2006 – 2006 Bachelor internship at Department of Blood Transfusion and Transplantation Immunology, University Medical Center, Nijmegen, the Netherlands under the supervision of Dr. H. Koenen. The effects of pterin-based immunosuppressive compounds on the generation of regulatory T cells were studied

Education and training

2008-2009 Radboud University Nijmegen Minor Biomedical Sciences / Immunology

2007-2008 Radboud University Nijmegen MSc Biomedical Sciences / Toxicology
•
Master thesis: The effect of small molecule T cell kinase inhibitors on cellular T cell function and histopathology of primary and secondary lymphoid organs.

2006-2007 Radboud University Nijmegen MSc Biomedical Sciences / Human pathobiology
•
Master thesis: Research into nuclear protein binding of regulatory T cell populations, on the promoter region of the FOX-P3 gene on behalf of T cell tolerance research.

2003-2006 Radboud University Nijmegen BSc Biomedical Sciences

1997-2003 Titus Brandsmalyceum (pre-university secondary education, grammar school)

Additional information

Publications

1. van der Kraan PM, van Caam APM, Blaney Davidson EN, van den Bosch MHJ, van de Loo FAJ. Growth factors that drive aggrecan synthesis in healthy articular cartilage. Role for transforming growth factor-β? Osteoarthr Cartil Open. 2024 Mar 7;6(2):100459.
2. Wang C, De Francesco R, Lamers LA, Rinzema S, Frölich S, van Lent PLEM, Logie C, van den Bosch MHJ. Transcriptomic profiling of osteoarthritis synovial macrophages reveals a tolerized phenotype compounded by a weak corticosteroid response. Rheumatology (Oxford). 2025 Feb 1;64(2):860-869.
3. van Kooten NJT, Blom AB, Teunissen van Manen IJ, Theeuwes WF, Roth J, Gorris MAJ, Walgreen B, Sloetjes AW, Helsen MM, Vitters EL, van Lent PLEM, Koëter S, van der Kraan PM, Vogl T, van den Bosch MHJ. S100A8/A9 drives monocytes towards M2-like macrophage differentiation and associates with M2-like macrophages in osteoarthritic synovium. Rheumatology (Oxford). 2025 Jan 1;64(1):332-343.
4. van den Bosch MHJ, Blom AB, van der Kraan PM. Inflammation in osteoarthritis: Our view on its presence and involvement in disease development over the years. Osteoarthritis Cartilage. 2024 Apr;32(4):355-364.
5. Bartels YL, van Lent PLEM, van der Kraan PM, Blom AB, Bonger KM, van den Bosch MHJ. Inhibition of TLR4 signalling to dampen joint inflammation in osteoarthritis. Rheumatology (Oxford). 2024 Mar 1;63(3):608-618.

6.Theeuwes WF, Di Ceglie I, Dorst DN, Blom AB, Bos DL, Vogl T, Tas SW, Jimenez-Royo P, Bergstrom M, Cleveland M, van der Kraan PM, Laverman P, Koenders MI, van Lent PL, van den Bosch MHJ. CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis. Arthritis Res Ther. 2023 Aug 31;25(1):158.
7.von Wulffen M, Luehrmann V, Robeck S, Russo A, Fischer-Riepe L, van den Bosch M, van Lent P, Loser K, Gabrilovich DI, Hermann S, Roth J, Vogl T. S100A8/A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis. Cell Rep. 2023 Aug 29;42(8):113006.
8.Thielen NGM, van Caam APM, V Beuningen HM, Vitters EL, van den Bosch MHJ, Koenders MI, van de Loo FAJ, Blaney Davidson EN, van der Kraan PM. Separating friend from foe: Inhibition of TGF-β-induced detrimental SMAD1/5/9 phosphorylation while maintaining protective SMAD2/3 signaling in OA chondrocytes. Osteoarthritis Cartilage. 2023 Nov;31(11):1481-1490.
9.Timmermans RGM, Blom AB, Nelissen RGHH, Broekhuis D, van der Kraan PM, Meulenbelt I, van den Bosch MHJ, Ramos YFM. Mechanical stress and inflammation have opposite effects on Wnt signaling in human chondrocytes. J Orthop Res. 2024 Feb;42(2):286-295.
10.Teunissen van Manen IJ, van Kooten NJT, Di Ceglie I, Theeuwes WF, Jimenez-Royo P, Cleveland M, van Lent PLEM, van der Kraan PM, Blom AB, van den Bosch MHJ. Identification of CD64 as a marker for the destructive potential of synovitis in osteoarthritis. Rheumatology (Oxford). 2024 Apr 2;63(4):1180-1188.
11.Vago JP, Valdrighi N, Blaney-Davidson EN, Hornikx DLAH, Neefjes M, Barba-Sarasua ME, Thielen NGM, van den

Bosch MHJ, van der Kraan PM, Koenders MI, Amaral FA, van de Loo FAJ. Gas6/Axl Axis Activation Dampens the Inflammatory Response in Osteoarthritic Fibroblast-like Synoviocytes and Synovial Explants. Pharmaceuticals (Basel). 2023 May 6;16(5):703.
12.van Gemert Y, Blom AB, Di Ceglie I, Walgreen B, Helsen M, Sloetjes A, Vogl T, Roth J, Kruisbergen NNL, Pieterman EJ, Princen HMG, van der Kraan PM, van Lent PLEM, van den Bosch MHJ. Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice. Osteoarthritis Cartilage. 2023 Jul;31(7):934-943.
13.van den Bosch MHJ, Blaney Davidson EN. Analysis of CCN4/WISP1 Effects on Joint Tissues Using Gain- and Loss-of-Function Approaches. Methods Mol Biol. 2023;2582:369-390.
14.Timmermans RGM, Blom AB, Bloks NGC, Nelissen RGHH, van der Linden EHMJ, van der Kraan PM, Meulenbelt I, Ramos YFM, van den Bosch MHJ. CCN4/WISP1 Promotes Migration of Human Primary Osteoarthritic Chondrocytes. Cartilage. 2023 Mar;14(1):67-75.
15.van Gemert Y, Kruisbergen NNL, Blom AB, van den Bosch MHJ, van der Kraan PM, Pieterman EJ, Princen HMG, van Lent PLEM. IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. Osteoarthritis Cartilage. 2023 Mar;31(3):340-350.
16.Evers BJ, Van Den Bosch MHJ, Blom AB, van der Kraan PM, Koeter S, Thurlings RM. Post-traumatic knee osteoarthritis; the role of inflammation and hemarthrosis on disease progression. Front Med (Lausanne). 2022 Aug 22;9:973870.
17.Kruisbergen NNL, van Gemert Y, Blom AB, van den Bosch MHJ, van Lent P. Activation of circulating monocytes by low-density lipoprotein a risk factor for Osteoarthritis? Rheumatology (Oxford). 2022 Dec 23;62(1):42-51.
18.Timmermans RGM, Bloks NGC, Tuerlings M, van Hoolwerff M, Nelissen RGHH, van der Wal RJP, van der Kraan PM, Blom AB, van den Bosch MHJ, Ramos YFM, Meulenbelt I. A human in vitro 3D neo-cartilage model to explore the response of OA risk genes to hyper-physiological mechanical stress. Osteoarthr Cartil Open. 2021 Dec 25;4(1):100231.
19.Kruisbergen NNL, Di Ceglie I, van Gemert Y, Walgreen B, Helsen MMA, Sloetjes AW, Koenders MI, van de Loo FAJ, Roth J, Vogl T, van der Kraan PM, Blom AB, van Lent P, van den Bosch MHJ. Nox2 Deficiency Reduces Cartilage Damage and Ectopic Bone Formation in an Experimental Model for Osteoarthritis. Antioxidants (Basel). 2021 Oct 22;10(11):1660.

20.Di Ceglie I, van Lent P, Geven EJW, Koenders MI, Blom AB, Vogl T, Roth J, van den Bosch MHJ. S100A8/A9 is not essential for the development of inflammation and joint pathology in interleukin-1 receptor antagonist knockout mice. Arthritis Res Ther. 2021 Aug 19;23(1):216.
21.Kruisbergen NNL, van Gemert Y, Walgreen B, Helsen MMA, Sloetjes AW, Koenders MI, van de Loo FAJ, Roth J, Vogl T, van der Kraan PM, Blom AB, van den Bosch MHJ, van Lent P. A single dose of anti-IL-1beta antibodies prevents Western diet-induced immune activation during early stage collagenase-induced osteoarthritis, but does not ameliorate end-stage pathology. Osteoarthritis Cartilage. 2021 Oct;29(10):1462-1473.
22.van Gemert Y, Kozijn AE, Pouwer MG, Kruisbergen NNL, van den Bosch MHJ, Blom AB, Pieterman EJ, Weinans H, Stoop R, Princen HMG, van Lent P. Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. Osteoarthritis Cartilage. 2021 Sep;29(9):1314-1323.
23.Theeuwes, W. F., van den Bosch, M. H. J., Thurlings, R. M., Blom, A. B. & van Lent, P. The role of inflammation in mesenchymal stromal cell therapy in osteoarthritis, perspectives for post-traumatic osteoarthritis: a review. Rheumatology (Oxford). 2021 Mar 2;60(3):1042-1053.
24.van den Bosch, M. H. J. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage. 2021 Feb;29(2):143-150.
25.Blom, A. B., van den Bosch, M. H., Blaney Davidson, E. N., Roth, J., Vogl, T., van de Loo, F. A., Koenders, M., van der Kraan, P. M., Geven, E. J. & van Lent, P. L. The alarmins S100A8 and S100A9 mediate acute pain in experimental synovitis. Arthritis Res Ther. 2020 Aug 27;22(1):199.
26.Ascone, G., Cao, Y., Jansen, I. D. C., Di Ceglie, I., van den Bosch, M. H. J., Blom, A. B., van Lent, P., Everts, V. & de Vries, T. J. Increase in the Number of Bone Marrow Osteoclast Precursors at Different Skeletal Sites, Particularly in Long Bone and Jaw Marrow in Mice Lacking IL-1RA. Int J Mol Sci. 2020 May 27;21(11):3774.
27.van den Bosch, M. H. J., van Lent, P. & van der Kraan, P. M. Identifying effector molecules, cells, and cytokines of innate immunity in OA. Osteoarthritis Cartilage. 2020 May;28(5):532-543.
28.Ascone, G., Di Ceglie, I., Walgreen, B., Sloetjes, A. W., Lindhout, E., Bot, I., van de Loo, F. A. J., Koenders, M. I., van der Kraan, P. M., Blom, A. B., van den Bosch, M. H. J. & van Lent, P. High LDL levels lessen bone destruction during antigen-induced arthritis by inhibiting osteoclast formation and function. Bone. 2020 Jan;130:115140.
29.Pieters, B. C. H., Cappariello, A., van den Bosch, M. H. J., van Lent, P., Teti, A. & van de Loo, F. A. J. Macrophage-Derived Extracellular Vesicles as Carriers of Alarmins and Their Potential Involvement in Bone Homeostasis. Front Immunol. 2019 Aug 8;10:1901.
30.Di Ceglie I, Blom AB, Davar R, Logie C, Martens JHA, Habibi E, Bottcher LM, Roth J, Vogl T, Goodyear CS, van der Kraan PM, van Lent PL, van den Bosch MH. The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK. FASEB J. 2019 Sep;33(9):10104-10115.
31.van Dalen, S. C. M., Blom, A. B., Walgreen, B., Sloetjes, A. W., Helsen, M. M. A., Geven, E. J. W., Ter Huurne, M., Vogl, T., Roth, J., van de Loo, F. A. J., Koenders, M. I., Casteilla, L., van der Kraan, P. M., van den Bosch, M. H. J. & van Lent, P. IL-1beta-Mediated Activation of Adipose-Derived Mesenchymal Stromal Cells Results in PMN Reallocation and Enhanced Phagocytosis: A Possible Mechanism for the Reduction of Osteoarthritis Pathology. Front Immunol. 2019 May 27;10:1075.
32.Di Ceglie I, Kruisbergen NNL, van den Bosch MHJ, van Lent P. Fc-gamma receptors and S100A8/A9 cause bone erosion during rheumatoid arthritis. Do they act as partners in crime? Rheumatology (Oxford). 2019 Aug 1;58(8):1331-1343.
33.Ascone, G., Di Ceglie, I., van den Bosch, M. H. J., Kruisbergen, N. N. L., Walgreen, B., Sloetjes, A. W., Lindhout, E., Joosten, L. A. B., van de Loo, F. A. J., Koenders, M. I., van der Kraan, P. M., Blom, A. B. & van Lent, P. High LDL-C levels attenuate onset of inflammation and cartilage destruction in antigen-induced arthritis. Clin Exp Rheumatol. 2019 Nov-Dec;37(6):983-993.
34.van den Bosch MHJ, Ramos YFM, den Hollander W, Bomer N, Nelissen RGHH, Bovee JVMG, van den Berg WB, van Lent PLEM, Blom AB, van der Kraan PM, Meulenbelt I. Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production. Rheumatology (Oxford). 2019 Jun 1;58(6):1065-1074.

35.van den Bosch MHJ. Inflammation in osteoarthritis: is it time to dampen the alarm-in this debilitating disease? Clin Exp Immunol. 2019 Feb;195(2):153-166.
36.van Dalen SCM, Kruisbergen NNL, Walgreen B, Helsen MMA, Sloetjes AW, Cremers NAJ, Koenders MI, van de Loo FAJ, Roth J, Vogl T, Blom AB, van der Kraan PM, van Lent P, van den Bosch MHJ. The role of NOX2-derived reactive oxygen species in collagenase-induced osteoarthritis. Osteoarthritis Cartilage. 2018 Dec;26(12):1722-1732.
37.Di Ceglie I, Ascone G, Cremers NAJ, Sloetjes AW, Walgreen B, Vogl T, Roth J, Verbeek JS, van de Loo FAJ, Koenders MI, van der Kraan PM, Blom AB, van den Bosch MHJ, van Lent PLEM. Fcgamma receptor-mediated influx of S100A8/A9-producing neutrophils as inducer of bone erosion during antigen-induced arthritis. Arthritis Res Ther. 2018 May 2;20(1):80.
38.Gran S, Honold L, Fehler O, Zenker S, Eligehausen S, Kuhlmann MT, Geven E, van den Bosch M, van Lent P, Spiekermann C, Hermann S, Vogl T, Schafers M, Roth J. Imaging, myeloid precursor immortalization, and genome editing for defining mechanisms of leukocyte recruitment in vivo. Theranostics 2018; 8: 2407-2423.
39.Cremers NAJ, van den Bosch MHJ, van Dalen S, Di Ceglie I, Ascone G, van de Loo F, Koenders M, van der Kraan P, Sloetjes A, Vogl T, Roth J, Geven EJW, Blom AB, van Lent P. S100A8/A9 increases the mobilization of pro-inflammatory Ly6Chigh monocytes to the synovium during experimental osteoarthritis. Arthritis Res Ther. 2017 Sep 29;19(1):217.
40.van den Bosch MH, Blom AB, Kram V, Maeda A, Sikka S, Gabet Y, Kilts TM, van den Berg WB, van Lent PL, van der Kraan PM, Young MF. WISP1/CCN4 aggravates cartilage degeneration in experimental osteoarthritis. Osteoarthritis Cartilage 2017; 25: 1900-1911.

41.van den Bosch MH, Blom AB, van de Loo FA, Koenders MI, Lafeber FP, van den Berg WB, van der Kraan PM, van Lent PL. Synovial Wnt signaling induces the expression of MMPs and is associated with disease progression in early symptomatic osteoarthritis patients. Arthritis Rheumatol. 2017 Oct;69(10):1978-1983.
42.Geven EJ, van den Bosch MH, Di Ceglie I, Ascone G, Abdollahi-Roodsaz S, Sloetjes AW, Hermann S, Schafers M, van de Loo FA, van der Kraan PM, Koenders MI, Foell D, Roth J, Vogl T, van Lent PL. S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis. Arthritis Res Ther. 2016 Oct 24;18(1):247.
43.van Dalen SC, Blom AB, Sloetjes AW, Helsen MM, Roth J, Vogl T, van de Loo FA, Koenders MI, van der Kraan PM, van den Berg WB, van den Bosch MH, van Lent PL. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage. 2017 Mar;25(3):385-396.
44.van den Bosch MH, Blom AB, Schelbergen RF, Koenders MI, van de Loo FA, van den Berg WB, Vogl T, Roth J, van der Kraan PM, van Lent PL. Alarmin S100A9 Induces Proinflammatory and Catabolic Effects Predominantly in the M1 Macrophages of Human Osteoarthritic Synovium. J Rheumatol. 2016 Oct;43(10):1874-1884.
45.de Munter W, van den Bosch MH, Sloetjes AW, Croce KJ, Vogl T, Roth J, Koenders MI, van de Loo FA, van den Berg WB, van der Kraan PM, van Lent PL. High LDL Levels Lead to Increased Synovial Inflammation and Accelerated Ectopic Bone Formation During Experimental Osteoarthritis. Osteoarthritis Cartilage. 2016 May;24(5):844-55.
46.van den Bosch MH, Gleissl TA, Blom AB, van den Berg WB, van Lent PL, van der Kraan PM. Wnts talking with the TGF-beta superfamily: WISPers about modulation of osteoarthritis. Rheumatology (Oxford). 2016 Sep;55(9):1536-47.
47.van den Bosch MH, Blom AB, Schelbergen RF, Vogl T, Roth JP, Sloetjes AW, van den Berg WB, van der Kraan PM, van Lent PL. Induction of Canonical Wnt Signaling by the Alarmins S100A8/A9 in Murine Knee Joints: Implications for Osteoarthritis. Arthritis Rheumatol. 2016 Jan;68(1):152-63.
48.Schelbergen RF, de Munter W, van den Bosch MH, Lafeber FP, Sloetjes A, Vogl T, Roth J, van den Berg WB, van der Kraan PM, Blom AB, van Lent PL. Alarmins S100A8/S100A9 aggravate osteophyte formation in experimental osteoarthritis and predict osteophyte progression in early human symptomatic osteoarthritis. Ann Rheum Dis. 2016 Jan;75(1):218-25.

49.van den Bosch MH, Blom AB, Sloetjes AW, Koenders MI, van de Loo FA, van den Berg WB, van Lent PL, van der Kraan PM. Induction of Canonical Wnt Signaling by Synovial Overexpression of Selected Wnts Leads to Protease Activity and Early Osteoarthritis-Like Cartilage Damage. Am J Pathol. 2015 Jul;185(7):1970-80.
50.Schelbergen RF, Geven EJ, van den Bosch MH, Eriksson H, Leanderson T, Vogl T, Roth J, van de Loo FA, Koenders MI, van der Kraan PM, van den Berg WB, Blom AB, van Lent PL. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.
51.van den Bosch MH, Blom AB, van Lent PL, van Beuningen HM, Blaney Davidson EN, van der Kraan PM, van den Berg WB. Canonical Wnt signaling skews TGF-beta signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal. 2014 May;26(5):951-8.
52.Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW, Mort JS, Vogl T, Roth J, van den Berg WB, van Lent PL. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. 2012 May;64(5):1477-87.

Projects

GRANT ACQUISITION (IN COMPETITION) AND PREDICATES

- NWO/ZonMW OffRoad. 100k€ (2023). Reversing macrophage paralysis to warrant long-term benefit of corticosteroid treatment in osteoarthritis.
- Junior Principle Investigator Predicate. 75k€/year (2021-2025)
- Dutch Research Council Talent Programme, NWO/ZonMW VENI. 250k€ (2019). Alarmed monocytes with Janus-faced behavior as the driving force behind OA pathology.
- Enabling Technology Hotels Grant from ZonMW: Development of HTS-compatible assay for identification of promoters and stabilizers for S100A8/S100A9 tetramerization. 30k€ (2017). Development of HTS-compatible assay for identification of promoters and stabilizers for S100A8/S100A9 tetramerization.
- Dutch Arthritis Foundation 240k€ (2017). Living on the edge: tight control of WISP1 expression is key for cartilage homeostasis.
- EMBO short term fellowship, 7.5k€ (2014) for a 3-month visit to the lab of Dr Marian Young, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda

Memberships

GOVERNING BOARD AND COMMITTEE ACTIVITIES
2024 – 2027 Chair of the OARSI Engagement Committee
2023 – 2027 Member of the OARSI Engagement Committee
2021 – 2023 Member of the OARSI Nominations Committee
2019 – 2020 Board Representative of the OARSI Young Investigator Committee
2019 – 2020 Chair of the OARSI Young Investigator Committee
2018 – 2021 Member of the OARSI Publications Committee
2017 – 2021 Member of the OARSI Young Investigator Committee

INTERNATIONAL ACTIVITIES
2008 – 2009 Minor internship at the Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, Scotland, UK under the supervision of Prof. R. Zamoyska. The influence of Lck availability on various responses to altered peptide ligands and basic cell signaling were studied in a murine OT-1 transgenic TCR system

2014-2014 Visiting PhD student at Marian Young’s lab at the NIDCR/NIH, Bethesda, MD. The effects of WISP1, a downstream target of canonical Wnt signaling, was studied in the induction of experimental osteoarthritis. This study was supported by an EMBO short-term fellowship

RESEARCH AWARDS

- OARSI Young Investigator Award, 2023
- EULAR Abstract Award Basic Science, 2016
- EWRR Poster Award, 2016
- OARSI Young Investigator Award, 2015
- EULAR Abstract Award Basic Science, EULAR 2012
- OARSI Young Investigator Award, 2012

INVITED LECTURES

- 'Year in Review – OA Biology' presentation at the Osteoarthritis Research Society International (OARSI) annual meeting, Vienna (2020)
- Invited speaker and member of researchers panel for a panel discussion for the 'Interactive Osteoarthritis Study Group'. American College of Rheumatology (ACR) annual meeting, San Diego (2017)

ORAL CONFERENCE PRESENTATIONS

- OARSI, Denver, 2023 (Young Investigator Award)
- OARSI, Vienna, 2020
- EULAR, Amsterdam, 2018 (2x)
- ACR, San Diego, 2017
- OARSI, Las Vegas, 2017
- ACR, Washington DC, 2016
- EULAR, London, 2016 (Abstract Award Basic Science)
- OARSI, Amsterdam, 2016
- ACR, San Francisco, 2015
- EULAR, Rome, 2015
- OARSI, Seattle, 2015 (2x) (Young Investigator Award)
- ACR, Boston, 2014
- NVR, Arnhem, 2014
- MBE, Rotterdam, 2014
- ORS, New Orleans, 2014
- EULAR, Madrid, 2013
- OARSI, Philadelphia, 2013
- ACR, San Diego, 2013
- ORS, San Antonio, 2013
- NVR, Arnhem, 2012
- EULAR, Berlin, 2012 (Abstract Award)
- OARSI, Barcelona, 2012 (Young Investigator Award)
- ORS, San Francisco, 2012
- ACR, Chicago, 2011
- NVR, Arnhem, 2011
- OARSI, San Diego, 2011

BOARD AND COMMITTEE ACTIVITIES

- Chair of the Osteoarthritis Research Society International (OARSI) Engagement Committee (2024-2027)
- Member of the Osteoarthritis Research Society International (OARSI) Engagement Committee (2023-2026)
- Member of the Osteoarthritis Research Society International (OARSI) Nomination Committee (2021-2023)
- Member of the Osteoarthritis Research Society International (OARSI) Task Force for a combinational grant application for Patient Education (2019-2020)
- Member of the Osteoarthritis Research Society International (OARSI) Board of Directors (2019-2020)
- Chair of the Osteoarthritis Research Society International (OARSI) Young Investigators Committee (2019-2020)
- Member of the Osteoarthritis Research Society International (OARSI) Young Investigators Committee (2017-2021)
- Member of the Osteoarthritis Research Society International (OARSI) Publications Committee (2017-2021)

Other Relevant Information

REVIEWER ACTIVITIES
Journals (manuscripts):

- Nature Communications
- Nature Reviews Rheumatology
- Annals of the Rheumatic Diseases
- Arthritis & Rheumatology
- Osteoarthritis and Cartilage

Osteoarthritis and Cartilage Open
•
Rheumatology
•
Arthritis Research & Therapy
•
Frontiers in Immunology
•
Frontiers in Pharmacology
•
Frontiers in Veterinary Science
•
Frontiers in Medicine
•
Journal of Cellular Biochemistry
•
Current Protocols

Funding agencies (grant proposals):
•
Dutch Arthritis Association (the Netherlands)
•
Deutsche Forschungsgemeinschaft (Germany)
•
Versus Arthritis (UK)
•
Research Foundation – Flanders (Belgium)
•
Trond Mohn Foundation (Norway)

TEACHING ACTIVITIES
2016 - present
•
Development of disease therapies: from target to therapy (BMS43: I have developed and given lectures, self-study assignments and interactive lectures)
•
Inflammatory diseases (BMS74: I have developed and given lectures, self-study assignments, practical courses and interactive lectures)
•
Inflammatory diseases (8RID: I have developed and given an interactive assignment)
•
State of the art research technologies in cancer, immunology and diagnostics (MIN08: lectures, practical courses and interactive lectures)
•
"Schade en herstel" (4MSH: lectures, interactive lectures and work groups)
•
"Aanval en verdediging" (1MAV: work groups and interactive lectures)
2011 - 2016
•
Molecular Pathobiology and Toxicology (PT01; practical courses and (interactive) lectures)

Cause and Effect in Tissue Damage (P003; practical courses and (interactive) lectures)
•
Mechanisms of Health and Disease (MGZ – 4MSH2C; (interactive) lectures / work groups)